Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 15

PMID 35159027

Authors

Mitesh Naik

Adil Al-Nahhas

Sairah R Khan

Affiliations

Soon will be listed here.

Abstract

Peptide receptor radionuclide therapy (PRRT) has been one of the most successful and exciting examples of theranostics in nuclear medicine in recent decades and is now firmly embedded in many treatment algorithms for unresectable or metastatic neuroendocrine neoplasms (NENs) worldwide. It is widely considered to be an effective treatment for well- or moderately differentiated neoplasms, which express high levels of somatostatin receptors that can be selectively targeted. This review article outlines the scientific basis of PRRT in treatment of NENs and describes its discovery dating back to the early 1990s. Early treatments utilizing Indium-111, a γ-emitter, showed promise in reduction in tumor size and improvement in biochemistry, but were also met with high radiation doses and myelotoxic and nephrotoxic effects. Subsequently, stable conjugation of DOTA-peptides with β-emitting radionuclides, such as Yttrium-90 and Lutetium-177, served as a breakthrough for PRRT and studies highlighted their potential in eliciting progression-free survival and quality of life benefits. This article will also elaborate on the key trials which paved the way for its approval and will discuss therapeutic considerations, such as patient selection and administration technique, to optimize its use.

Citing Articles

Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers.

Pekec T, Venkatachalapathy S, Shim A, Paysan D, Grzmil M, Schibli R Sci Rep. 2023; 13(1):20662.

PMID: 38001169 PMC: 10673941. DOI: 10.1038/s41598-023-47287-2.

Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy.

Khessib T, Khessib S, Berry G, Aparici M Radiol Case Rep. 2023; 18(11):3945-3948.

PMID: 37680654 PMC: 10480434. DOI: 10.1016/j.radcr.2023.07.044.

Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer.

Grzmil M, Wiesmann F, Schibli R, Behe M Cancers (Basel). 2023; 15(1).

PMID: 36612012 PMC: 9817840. DOI: 10.3390/cancers15010017.

References

Claringbold P, Turner J . NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study. Cancer Biother Radiopharm. 2015; 30(6):261-9. DOI: 10.1089/cbr.2015.1876. View

Partelli S, Bertani E, Bartolomei M, Perali C, Muffatti F, Grana C . Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery. 2017; 163(4):761-767. DOI: 10.1016/j.surg.2017.11.007. View

Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J . Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg. 2009; 395(2):185-92. DOI: 10.1007/s00423-009-0520-x. View

Klimstra D, Modlin I, Coppola D, Lloyd R, Suster S . The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6):707-12. DOI: 10.1097/MPA.0b013e3181ec124e. View

Sandstrom M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Roman U . Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015; 2(1):24. PMC: 4883125. DOI: 10.1186/s40658-015-0127-y. View

Sabet A, Haslerud T, Pape U, Sabet A, Ahmadzadehfar H, Grunwald F . Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 41(2):205-10. DOI: 10.1007/s00259-013-2547-z. View

Zandee W, Brabander T, Blazevic A, Kam B, Teunissen J, Feelders R . Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2018; 104(4):1336-1344. DOI: 10.1210/jc.2018-01991. View

Reubi J, Kvols L, Waser B, Nagorney D, Heitz P, Charboneau J . Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990; 50(18):5969-77. View

de Keizer B, van Aken M, Feelders R, de Herder W, Kam B, Van Essen M . Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008; 35(4):749-55. PMC: 2668649. DOI: 10.1007/s00259-007-0691-z. View

10.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

11.

Adams S, Baum R, Rink T, Usadel K, Hor G . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998; 25(1):79-83. DOI: 10.1007/s002590050197. View

12.

Gains J, Moroz V, Aldridge M, Wan S, Wheatley K, Laidler J . A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020; 47(10):2348-2357. DOI: 10.1007/s00259-020-04741-x. View

13.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M . Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018; 36(25):2578-2584. PMC: 6366953. DOI: 10.1200/JCO.2018.78.5865. View

14.

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul J . High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014; 55(11):1786-90. DOI: 10.2967/jnumed.114.144386. View

15.

Sorbye H, Kong G, Grozinsky-Glasberg S . PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2019; 27(3):R67-R77. DOI: 10.1530/ERC-19-0400. View

16.

Al-Nahhas A . Nuclear medicine imaging of neuroendocrine tumours. Clin Med (Lond). 2012; 12(4):377-80. PMC: 4952131. DOI: 10.7861/clinmedicine.12-4-377. View

17.

Gains J, Bomanji J, Fersht N, Sullivan T, DSouza D, Sullivan K . 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. J Nucl Med. 2011; 52(7):1041-7. DOI: 10.2967/jnumed.110.085100. View

18.

Krebs S, Pandit-Taskar N, Reidy D, Beattie B, Lyashchenko S, Lewis J . Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2018; 46(3):677-685. PMC: 6447060. DOI: 10.1007/s00259-018-4193-y. View

19.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

20.

Khan S, Krenning E, Van Essen M, Kam B, Teunissen J, Kwekkeboom D . Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011; 52(9):1361-8. DOI: 10.2967/jnumed.111.087932. View